Cerebral deposition of ␤-amyloid (A␤) is an invariant event of Alzheimer's disease (AD). We recently described that the brain of aged transgenic mice expressing anti-nerve growth factor (NGF) antibodies (AD11 mice) show a dramatic neurodegenerative phenotype, reminiscent of AD, which includes neuronal loss, cholinergic deficit, and tau hyperphosphorylation, associated with neurofibrillary pathology. We now report that brains of aged transgenic mice contain large amounts of ␤-amyloid plaques and describe their morphology by a variety of approaches. In conclusion, the chronic deprivation of NGF leads to the formation and deposition of A␤ in AD11 mice, suggesting a direct link between NGF signaling and abnormal processing of amyloid precursor protein.
INTRODUCTION
Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system characterized by the accumulation of abnormally processed proteins in neurofibrillary tangles and senile plaques (Selkoe, 2001) . These neurodegenerative hallmarks are common to familial and sporadic forms of the disease, and different pathways, factors, and causes may ultimately lead to the neuropathology described as AD.
The major proteinaceous component of AD senile plaques is a 4-kDa peptide of 39 -43 amino acids named ␤-amyloid (A␤) (Glenner and Wong, 1984; Masters et al., 1985; Kang et al., 1987; Mori et al., 1992) , derived from a larger precursor protein named amyloid protein precursor (APP) (Kang et al., 1987; Ponte et al., 1988; de Sauvage and Octave, 1989) . A␤ is derived from APP after cleavage by ␤-and ␥-secretase (Seubert et al., 1993; Selkoe and Wolfe, 2000) . APP processing yields numerous A␤ species with extensive amino and carboxyl terminal heterogeneity (Golde et al., 2000) . Among these, the 4-kDa major species in human CSF and brain are A␤ 1-40 and A␤ .
Mutations in human APP (hAPP) gene (Goate et al., 1991) , leading to increased extracellular deposition of A␤, underlie early onset forms of AD. hAPP genes harboring these mutations have been introduced in transgenic mice, which indeed show an increase of the extracellular content of A␤ and A␤ and display a high load of ␤-amyloid plaques, thus demonstrating that A␤ metabolism is changed in a way that promotes aggregation and deposition (Janus et al., 2000) . Mutant hAPP mice therefore represent models for the familial forms of AD, despite the fact that they show a rather limited overall neurodegenerative phenotype. On the other hand, no comprehensive model for the sporadic forms of AD was described until recently. We derived a line of transgenic mice (AD11 mice), expressing recombinant antibodies neutralizing nerve growth factor (NGF) . Aged AD11 mice reproduce a complex and comprehensive neurodegenerative phenotype, including neuronal loss, cholinergic deficit, behavioral impairment, tau hyperphosphorylation , and cholinergic dependent impairments of cortical synaptic plasticity (Pesavento et al., 2002) . AD11 mice can be therefore considered a comprehensive model for sporadic AD. However, although an altered processing of APP was also shown in AD11 mice , the presence of ␤-amyloid plaques was not described.
In this study, to further characterize AD11 mice as a model for AD-like neurodegeneration, we demonstrate by a variety of techniques the presence of A␤ in the brains of AD11 mice and its accumulation in extracellular plaques. The results provide a further validation of AD11 mice as a model for sporadic AD and suggest a direct link between NGF signaling and abnormal processing of APP.
RESULTS

Antibodies against A␤-Amyloid Peptides Label Plaques in Aged AD11 Mice
The presence of A␤ amyloid plaques was investigated using a panel of antibodies directed against different epitopes of the A␤ peptide and previously used for similar purposes to those of the present study. MAb 4G8 recognizes A␤ 17-24 and has been widely used to detect A␤ plaques in APP and presenilin 1 (PS1) transgenic mice (Hsiao et al., 1996; Borchelt et al., 1997) . The polyclonal antibody R3660 recognizes the N-terminal pyroglutamate residue at position 3 and the l-aspartate residue at position 1 of A␤ sequence (Russo et al., 2001) . The antibody against A␤ 1-40 was derived from a synthetic peptide corresponding to ␤-APP 672-711 . The anti-A␤ 1-42 has been used to test the presence of this peptide in PS1 mice and APP nNLH mice (Borchelt et al., 1997; Savage et al., 1998) and was reported not to cross-react with A␤ 1-40 and A␤ . Finally, the antibody F2580 is specific for the C-terminus of APP (Russo et al., 2001) .
In aged AD11 anti-NGF mice, antibodies directed against the NH 2 -terminus of A␤ and A␤ 17-24 , labeled neuritic dense cored plaques in the hippocampus (Fig.  1A) and cerebral cortex. Deposition was virtually absent in nontransgenic control mice (Fig. 1B) . The forms of A␤ deposition varied, although the most abundant type of plaque was the one characterized by a central compact core surrounded by dystrophic neurites and A␤-positive cells (Fig. 1C) . These plaques ranged up to 140 m in diameter, averaging around 60 -100 m. In sections from human AD brains, antibodies against the NH 2 -terminus of A␤ 1-40 -, A␤ 1-42 -, A␤ 17-24 -labeled classical plaques characterized by a central empty region surrounded by a halo of dystrophic neurites (Fig. 1D) . Antibodies against the C-terminal of APP, the NH 2 -terminus of A␤ and against A␤ 1-42 labeled also nonneuritic compact plaques in the hippocampus from both AD11 mice (Fig. 1E ) and human AD brain (Fig. 1F) . In AD11 mice the overall average diameter of these plaques was 30 m. Cerebrovascular A␤ deposition was found consistently throughout cerebral cortex, hippocampus, and thalamus of aged AD11 mice with antibodies against A␤ 1-40 , A␤ and A␤ [17] [18] [19] [20] [21] [22] [23] [24] (Fig. 1G ) and was completely absent in nontransgenic mice (Fig. 1H) . Leptomeningeal vessels were also heavily affected. Nontransgenic littermate mice showed none of these neuropathological changes.
The use of antibodies against A␤ 1-40 and A␤ 1-42 allowed detecting the presence of neuritic compact plaques in the hippocampus (A␤ 1-40 , Fig. 2A ; A␤ 1-42 , Fig.  2B ). The presence of small (20 -25 m) compact, stellate nonneuritic plaques was also detected by anti-A␤ 1-42 in the cortex of AD11 anti-NGF mice, mixed to positive cell bodies (Fig. 2C ).
The specificity of the staining was confirmed by preincubation of anti-A␤ 17-24 antibodies with the corresponding peptide antigen (Fig. 3) . A␤-positive cells and plaques were detected using antibodies against A␤ [17] [18] [19] [20] [21] [22] [23] [24] , and preincubation of the antibodies with the A␤ peptide abolishes the staining of amyloid plaques in sections from AD11 mice (Fig. 3C) .
Quantification of the A␤ Burden and A␤ Levels in AD11 Mice
The amyloid burden was evaluated in the hippocampus of aged AD11 mice with antibodies against A␤ 17-24 , showing that 6.1 Ϯ 1.7% of the area was occupied by plaques. Two animals were excluded from the determination of the average amyloid burden, giving an amyloid burden of 13.5 and 24.2%, respectively. The amyloid burden in nontransgenic control mice was equal to zero.
The levels of the insoluble pool of brain amyloid peptides A␤ 1-40 and A␤ were measured in AD11 mice by ELISA. The analysis was performed on the formic acid fraction of brain extracts, thought to contain plaque associated peptides. Biochemical analysis was paralleled by immunohistochemistry on the other hemisphere. The assay for total A␤ was linear in the range between 15.75 and 500 pmol/ml (Fig. 4A) . The A␤ 1-40 assay was linear between 15.62 and 250 pmol/ml (Fig. 4B) , and the A␤ 1-42 assay was linear between 7.4 and 250 pmol/ml (Fig. 4C) .
The levels of total A␤ was equal to 900 Ϯ 50 fmol/g extract (Fig. 4D) . The levels of A␤ 1-40 were 83 Ϯ 5 fmol/g extract ( Fig. 4D ) and for A␤ 1-42 were equal to 150 Ϯ 10 fmol/g (Fig. 4D) . In nontransgenic control mice A␤ 1-40 and A␤ 1-42 were undetectable. The ratio between A␤ 1-40 and A␤ 1-42 was equal to 0.55.
The presence of the 4-kDa species of A␤ was also confirmed by Western blot analysis. Formic acid extracts from AD11 and age-matched control mice were run in parallel with samples from AD human brain. In both human and AD11 mice a 4-kDa band was revealed using mAb 4G8 (Fig. 4E , lanes 1 and 3). No 4G8 labeling was observed in the lane corresponding to age-matched control mice (Fig. 4E , lane 2). The experiment was performed at least three times, with extracts from six different animals.
Absence of A␤ Deposition in the Cerebellum, Neostriatum, and Locus Coeruleus of AD11 Mice
The distribution of A␤ compact plaques was also assessed in brain regions that are known to be relatively spared in AD and to display only diffuse plaques in AD human brain, such as the neostriatum and the cerebellum (Cataldo et al., 1996) . In the cerebellum of AD11 mice, the antibody against A␤ 17-24 labeled Purkinje neurons ( Fig. 5B ) while antibodies against A␤ 1-40 ( Fig. 5C ), against A␤ 1-42 ( Fig. 5D ), and against the NH 2 -terminus of A␤ (data not shown) labeled only scattered microglial cells. No plaque was found in this area. No labeling whatsoever was observed in nontransgenic control mice (Fig. 5A ).
In the striatum of AD11 mice, the antibodies against A␤ 17-24 , A␤ 1-40 , and A␤ 1-42 labeled only large neostriatal cells (Figs. 5F-5H). This labeling was not observed in control mice (Fig. 5E ). No plaques were found in the striatum.
The locus coeruleus (LC) is a brain stem nucleus which displays neuronal loss and tangles in AD patients (Palmer and DeKosky, 1993) . In AD11 mice, the central portion of LC displays shrunken cells that are labeled with the antibodies against A␤ [17] [18] [19] [20] [21] [22] [23] [24] (Fig. 5J) , A␤ (Fig. 5K) , and A␤ (Fig. 5L ), but no plaque was found. No labeling was observed in nontransgenic control mice ( Fig. 5I ) and in regions surrounding the LC nucleus (Figs. 5J-5L).
In conclusion, no A␤ plaques were observed in neostriatum, cerebellum, and locus coeruleus of AD11 mice.
Fibrillary and Amyloid Changes Detected by Silver Impregnation Methods and Thioflavin S
Further characterization of neurofibrillary changes and amyloid deposition in AD11 mice was given using histological techniques such as Campbell-Switzer and Gallyas silver impregnation techniques and thioflavin S staining.
The Campbell-Switzer method allowed us to reveal, in AD11 mice, the presence of many intensely black stained cells (Fig. 6C) , in analogy to what is found in AD human brains (Fig. 6D ). These very dark stained cells were virtually absent and much weakly labeled in nontransgenic control mice (Fig. 6A ) and in brain sections from human nondemented individuals (Fig. 6B) . The Campell-Switzer method allowed also us to show the presence of different forms of amyloid deposition. Both in AD11 (Fig. 6C ) and in human AD (Fig. 6D) brains, compact plaques assumed a brown color and were surrounded by black cells. Diffuse plaques were more easily observed in the molecular layers of the hippocampus (Fig. 6E ) while fleecy plaques were observed in the infragranular layers of cerebral cortex (Fig. 6F) . A second form of compact plaques is found in human AD brains, where the neuritic halo were intensely stained black (Fig. 6H) . The average diameter of these plaques was 70 -80 m. In AD11 mice this type of plaques was not observed, while another type of fibrillar deposition was found (Fig. 6G ), surrounded by a halo of packed and thick black bundles (Fig. 6G) .
Gallyas silver impregnation is considered one of the methods of choice to evaluate the neurofibrillary pathology in the course of Alzheimer's-type neurodegeneration (Braak and Braak, 1997) In AD11 mice, Gallyas silver impregnation revealed intensely stained cells, filled with structures reminiscent of neurofibrillary tangles and dystrophic neurites (Fig. 7A ). Virtually no staining was detected in nontransgenic control mice (Fig. 7B) . Plaques with fibrillary depositions were also found in AD11 mice (Fig. 7C ), similar to those found in human AD brains (Figs. 7D and 7F). In both AD11 mouse and AD human tissues, filament bundles are found and assumed a regular structure in the mouse (Figs. 7C and 7E) while in the human they had no discernible structure (Figs. 7D and 7F) . In AD11 and human brains, plaques are encircled by tangle-like structures (Figs. 7E and 7F) .
Cells with ameboid shape, suggestive of activated glia, were observed in AD11 mice (asterisks, Figs. 7C and 7E). The actual presence of activated microglia was demonstrated by double immunohistochemistry against MAC-1 and A␤ 1-42 . MAC-1 labeled cells surrounding plaques and, in general, in the parenchyma (Fig. 8A) . Antibodies against MAC-1 label also the central core of the plaque (in yellow, Fig. 8A ). Double immunohistochemistry was also used to reveal that plaques are surrounded by cells that are both positive for phosphotau-tau and for A␤ (Fig. 8B) . In both Fig.  8A and Fig. 8B , some dystrophic neurites and cellular debris are shown, surrounding the plaque.
Several sections showed compact plaques that showed birefringence after Congo red staining (data not shown). These plaques were also stained with thioflavin S (Fig. 8C) . Some cells associated with plaques were also thioflavin S positive (Fig. 8C) . However, the overall morphology and staining intensity of thioflavin-positive plaques in AD11 mice was different from that observed in human AD brains (Fig. 8D) , where thioflavin S labeled all type of plaques, with a much brighter staining.
DISCUSSION
The deposition of A␤ plays an important role in the pathogenesis of AD, as the main component of senile plaques (Selkoe, 2001) . The formation of amyloid plaques is thought to result from the interplay of an abnormal processing of APP and a permissive neuronal context, such as the human brain. Indeed, mice and rats do not develop spontaneously amyloid plaques, unlike other species (De Strooper and Van Leuven, 1998) . Also, a simple overexpression of entire wild-type human APP in transgenic mice fails to induce the formation of amyloid plaques (Mucke et al., 2000) , which are only formed if the mutant forms of the hAPP gene are expressed (Janus et al., 2000) .
We previously demonstrated that the neurodegenerating cortex of AD11 transgenic mice contains numerous extracellular deposits, detected with antibodies to non A␤ regions of APP, including antibodies to the C-terminal region of APP . Interestingly, C-terminal fragments of APP, as well as fulllength APP were shown to accumulate extracellularly in rat brain after cerebral ischemia (Pluta et al., 1994) . In human AD brains, antibodies to non-A␤ regions of APP detect a subset of senile plaques (Joachim et al., 1991) . Moreover, the antibodies that were used to reveal the extracellular deposits of APP in AD11 mice also revealed similar deposits in human AD brains (SC, SG, and AC, unpublished observation). However, although these results suggest the presence of an altered metabolism of APP in AD11 mice, and although an altered processing of APP in AD11 mice was shown at the biochemical level , the presence of ␤-amyloid plaques, containing the A␤ peptide was not yet described in AD11 mice.
In this study, we present further evidence that amyloidogenic forms of APP, containing A␤-region epitopes, are produced in the brain of aged AD11 mice. Antibodies directed against different A␤4 epitopes labeled neuritic and nonneuritic compact plaques in the hippocampus and the cerebral cortex. The neuritic compact plaques of AD11 mice differ from those found in human AD brains, while the nonneuritic ones are more similar to their AD counterparts. The difference in mor- phology of neuritic compact plaques could be in part attributable to the observation that, in mice, substitutions of the A␤ sequence could inhibit formation of ␤-sheet structures implicated in plaque formation (Johnstone et al., 1991) .
Campbell-Switzer silver staining allows recognizing two more types of amyloid plaques in AD11 mice: diffuse nonneuritic plaques and fleecy amyloid plaques, resembling those similarly found in layer VI of human AD entorhinal cortex (Thal et al., 1999) . As reported in human AD brains, also in AD11 mice neuritic plaques are associated with phosphotau immu- noreactivity and with neurofibrillary depositions, revealed here by Gallyas silver staining. The presence of phosphotau in ␤-amyloid plaques, and the Gallyas widespread positivity, add new evidence to the presence of a severe neurofibrillary pathology in AD11 mice . The nature of these cytoskeletal changes could be distinct from one another. Indeed, cytoskeletal changes can be linked not only to alterations in the processing of tau, but crucially involve also neurofilament proteins (Vickers et al., 2000) . Dystrophic neurites and tangle filled cells revealed by Gallyas silver staining could be topographically and morphologically distinct from those detected by the anti-phosphotau antibody.
In AD11 mice, activated glial cells surround the ␤-amyloid plaques, as suggested by Gallyas silver staining and shown by double-staining with A␤ and the MAC-1 microglia marker. Moreover, we show MAC-1 (an ␣M␤ 2 -integrin) immunoreactivity associated with compact A␤ 1-42 -positive plaques, as reported in human AD brains (Akiyama et al., 2000) .
Comparing the classification of A␤ plaques in human and AD11 mice, we grouped plaques in AD11 mice according to the division proposed by Esiri et al. (1996) ,   FIG. 7 . Gallyas staining. Gallyas silver impregnation staining reveals black-stained intracellular neurofibrillary deposition in aged AD11 anti-NGF mice (A) and not in control mice (B). In A, arrows point to dystrophic neurites. Black-stained plaques are also shown in AD11 anti-NGF mice (C) and human AD brains (D). Plaques are surrounded by black stained cells (arrows) and by activated microglia (asterisks). The insets are enlarged in (E) and (F). Arrows point to dystrophyc neurites (E, F) while asterisks are placed in correspondence of ameboid-shaped glial cells (E). Bar in A-D, 25 m; inset, 12.5 m.
which divides senile plaques in four categories: diffuse neuritic plaques, diffuse nonneuritic plaques, dense cored (compact) neuritic plaques, and dense cored nonneuritic plaques. The data presented led us to the conclusion that in AD11 mice the last three types of plaques are observable. In particular, compact nonneuritic plaques and diffuse nonneuritic plaques have been associated with early and advanced stages of neurodegeneration in AD, respectively (Yamaguchi, 1998) .
Insights in the pathogenesis of neurodegeneration in AD11 mice are given by the intraneuronal accumulation of the A␤ 1-42 peptide and by A␤ deposition in cerebral blood vessel wall. Indeed, early intraneuronal accumulation of A␤ 1-42 (Gouras et al., 2000) and ␤-amyloid deposition in the walls of meningeal and cerebral blood vessels (Vinters, 1987) have been suggested to contribute to the pathogenesis of AD.
At the biochemical level, we confirmed by Western blot analysis the presence of the 4-kDa species of A␤ in formic acid extracts from AD11 mice and also demonstrated the presence of a significant pool of insoluble (formic acid soluble) A␤, with an A␤ 1-40 /A␤ 1-42 ratio (35/65) that approximates that reported for human AD brains (A␤ 1-40 /A␤ 1-42 ratio 15:85). Interestingly, we observed a discrepancy between the total amount of A␤ and the sum of the measured levels of A␤ 1-40 plus A␤ . This could be due the presence of a heterogeneous mixture of different ␤ amyloid variants. Indeed, mAb 4G8 and the polyclonal antibody R3660, used to evaluate the total amount of A␤, could variously detect ␤-amyloid peptides of different sizes, derived from the proteolytic processing of APP. The presence of different ␤-amyloid variants with extensive amino and carboxy terminal heterogeneity has been described (Greenfield et al., 1999; Golde et al., 2000) .
In conclusion, our studies indicate that A␤ peptides are present in AD11 mice and that A␤-containing amyloid plaques are formed in AD11 mice. The detailed biochemical and structural characterization of the processing of APP in AD11 mice awaits further investigations. Our findings add a missing piece of evidence to the overall picture of the neurodegenerative phenotype observed in AD11 mice, which is now even more closely reminiscent of Alzheimer-like neurodegeneration.
Etiologically, AD is heterogeneous (St. George-Hyslop et al., 1990 ). Yet, the clinical phenotype and the neuropathological lesions are not distinctly different among the different forms of AD. Therefore, there may be different causes that initiate pathways which, at some point, merge into a common pathogenic mechanism, giving rise to the common aspects of AD. Mutations in APP, presenilin 1, and presenilin 2, giving rise to familial forms of the disease, may involve one (or more?) of these pathways, whose correspondence to the more abundant sporadic forms is not yet clear. The transposition of the APP and presenilin mutations to transgenic mice has met with some success, even if the rather limited neurodegeneration observed, in addition to A␤ deposition, leaves clearly room for improvement (Staufenbiel and Sommer, 1998; Janus et al., 2000) . The lack of an adequate model for sporadic AD underlines the need to study alternative pathways ultimately impinging on the common AD endpoints.
The AD11 model, which encompasses three main aspects of AD, cholinergic deficits, neurofibrillary pathology, and ␤-amyloid deposition, appear to constitute a comprehensive model for the sporadic forms of the disease. In addition to provide a useful experimental model, AD11 mice demonstrate a link between the intracellular and intercellular signaling of NGF through p75 and TrkA receptors on target cells and the processing of Alzheimer's endpoints such as APP and tau, within the context of a well-defined synaptic pathway, the cholinergic neurons projecting from the basal forebrain to the cortex.
How do we rationalize these links into a conceptual mechanistic framework? The connection between NGF deficits and AD neurodegeneration has been previously suggested (Hefti et al., 1989) . A prediction coming from AD11 model is that an imbalance or block in NGF signaling pathway or in NGF transport system could be present in AD. Whether and how the observed phenotype depends on NGF neutralization per se or whether it also depends crucially on antibodies mediating such neutralization are questions for future work.
The mechanism(s) whereby neutralizing NGF activity leads in aged AD11 mice to such a complex neurodegeneration may find a conceivable starting point in the cholinergic deficit in the basal forebrain induced by anti-NGF antibodies. Links between the cholinergic system and APP metabolism have been described (Nitsch et al., 1992; Ro␤ner et al., 1998a) , suggesting that cortical APP processing is under basal forebrain cholinergic control, possibly mediated through muscarinic M1 receptors on cholinoceptive cortical target cells. Lesions of rat cholinergic system with p75 immunotoxins lead to a decrease in the abundance of secreted APP and a concomitant increase in membrane-bound APP (Ro␤ner et al., 1997) , but no evidence for plaque deposition was found.
APP expression and processing have been shown to be under the direct regulatory control of NGF, via in-dependent and potentially conflicting signaling through p75 and TrkA receptors (Ro␤ner et al., 1998b) . Thus, an imbalance in this two-receptor system (Chao and Hempstead, 1995) , determined by a variety of different causes, may have direct effects on APP processing and on the homeostatic mechanisms regulating hippocampal and cortical NGF, APP, and cholinergic activity.
The formation of amyloid plaques in the mouse brain is noteworthy, since it is generally thought that due to amino acid differences in the NH 2 -terminal region of A␤, mouse amyloid shows a reduced tendency to aggregate (De Strooper and Van Leuven, 1998) . AD11 mice represent the only rodent model where amyloid plaques develop without overexpression of mutated human APP. One possible explanation for this is that the activity of ␤-secretase (BACE) or ␥-secretase are regulated by NGF receptor signaling, in ways to be determined. Given the diversity of sites of action of NGF in the CNS, and the widespread cholinergic innervation to the cortex, there may be more than one site of action of the anti-NGF antibodies leading, through parallel dependent or independent pathways, to APP and tau neuropathology. Rescue experiments by agents acting at different levels will allow this mechanistic question to be addressed.
EXPERIMENTAL METHODS
Production of AD11 Mice
Generation of AD11 transgenic mice has been described previously . AD11 mice express a recombinant version of the monoclonal antibody ␣D11 that specifically recognize and neutralize NGF (Cattaneo et al., 1988; Molnar et al., 1998; Capsoni et al., 2000; Ruberti et al., 2000) . A total of 21 male and female AD11 mice and nontransgenic littermate control mice have been used for this study. 
Histochemistry and Immunohistochemistry
Brains from AD11 mice and control mice, aged 15 months, were fixed in 4% paraformaldehyde/phosphate-buffered saline (PBS) solution for 24 h and then cryoprotected in 30% sucrose. Brains were microtomed at 12 m, and sections were collected in six-well plates containing 1% paraformaldehyde/PBS. A set of experiments was performed by incubating in parallel mouse and human sections. The latter were obtained from AD human brains supplied by the Netherlands Brain Bank.
The presence of neurofibrillary pathology was assessed using the Gallyas silver impregnation method (Gallyas and Merchenthaler, 1988) . Amyloid deposits were revealed using Congo red, thioflavin S, and Campbell-Switzer silver impregnation method (Campbell, Switzer, and Martin, "13th Annual Meeting Society for Neuroscience," Abstract 678, 1987). Specifically, the Gallyas silver-iodide technique was used to reveal neurofibrillary changes and colocalizes with tau protein (Iqbal et al., 1991) , while the Campbell-Switzer silverpyridine technique is know to be associated to brain amyloid pathology (Braak and Braak, 1997; Thal et al., 1999) .
Immunohistochemical detection of amyloid was performed using with antibodies raised against A␤ [17] [18] [19] [20] [21] [22] [23] [24] (mAb 4G8, Senetek, Maryland Heights, MO), A␤ 1-40 (Sigma, St Louis, MO), and anti A␤ 1-42 (Biosource International, Camarillo, CA). The antibodies against the NH 2 -terminus of A␤ and the C-terminus of APP were provided by Professor Schettini and Dr. Russo (Advanced Biotechnology Center, University of Genova, Italy; Russo et al., 2001) .
All antibodies were incubated for 72 h at 4°C (Thal et al., 1999) . The prolonged time of incubation allowed reducing the concentration of primary antibodies. This was particularly useful to decrease the amount of background given by monoclonal antibodies raised in mouse, such as mAb 4G8, and increase the specificity of staining. The primary antibodies were detected using the biotinylated secondary antibodies and the ABC method developed with nitrobluetetrazolium and 5-bromo-4-chloro-3-indolyl phosphate toluidinium salt or 3,3Ј-diaminobenzidine.
To verify the specificity of anti-A␤ immunolabeling, the primary antibodies, prior of incubation, were preadsorbed for 1 h against respective peptides. MAb 4G8 was preadsorbed against a fragment of A␤ protein including residues 12-28 (Research Biochemicals International, Natick, MA), while polyclonal antibodies against A␤ 1-40 and A␤ 1-42 were preadsorbed against the respective peptides (Bachem AG, Bubendorf, Switzerland). Double immunohistochemistry was performed using the anti-A␤ 1-42 antibody and anti-phosphotau mAb AT8 (Innogenetics, Zwijnaarde, Belgium) or the rat antimouse CD11b (MAC-1 ␣ chain) antibody (BD PharMingen, San Diego, CA). The reaction was revealed using fluorescein isothiocyanate-conjugated anti-rabbit or anti-rat (Sigma) and tetramethylrhodamine isothiocyanate-conjugated anti-mouse (Sigma) or anti-rabbit antibodies.
Amyloid Burden
The amyloid burden was quantified by image analysis on anti-A␤ 17-24 -stained sections as described (Schenk et al., 1999) , using the Optimas 6.1 video image analysis system (Optimas) linked to a Zeiss Axiovert microscope through a CCD video camera.
ELISA
To quantify the ratio between insoluble A␤ 1-40 and insoluble A␤ 1-42 brains were removed and homogenized as described before (Games et al., 1995; Ishihara et al., 1999) . Briefly, the soluble fraction of A␤ was separated by the formic acid soluble fraction by homogenizing the tissue in ice-cold RAB high-salt buffer (0.1 M morpholineethanesulfonic acid, 1 mM EGTA, 0.5 mM MgSO 4 , 0.75 M NaCl, 0.02 M NaF, 1 mM phenylmethylsulfonyl fluoride, protease inhibitor cocktail (Complete mini, Roche Diagnostics), 100 mM EDTA, pH 7.0), followed by rehomogenization in 1 M sucrose/RAB and RIPA buffer (50 mM Tris, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 0.5% sodium deoxycholate, and 1% SDS, pH 8.00). The pellet was then rehomogenized in 70% formic acid. The analysis was performed only on the formic acid fraction. Extracts were then neutralized by a 1:10 dilution in 0.5 M Tris base (pH 9.5).
A sandwich ELISA was performed (Skovronsky, 2000) . To detect A␤ 1-40 and A␤ 1-42 mAb 4G8 was used as capturing antibody while polyclonal antibodies against A␤ 1-40 and A␤ 1-42 were used for detection. Specificity of this ELISA for A␤ 1-40 and A␤ 1-42 was tested by comparing signals generated with antibodies against A␤ 1-42 and A␤ 1-40 , respectively. To detect total A␤, the antiserum R3660 against the NH 2 -terminus of A␤ was used.
Samples were diluted in EC buffer (0.1 M Na 2 HPO 4 , 2 mM EDTA, 0.4 M NaCl, 0.2% BSA, 2% skimmed milk, 0.05% CHAPS, 0.05% sodium azide). A standard curve using synthetic A␤ or A␤ 1-42 peptides (Bachem AG, Bubendorf, Switzerland) was used to calculate A␤ con-centration in the brain of AD11 mice. Nontransgenic control mice were processed in parallel with the transgenic tissue. The sensitivity of the ELISA for A␤ 1-40 and A␤ 1-42 was 10 pmol/ml.
Western Blotting
Biochemical analysis of A␤ was performed as described previously (Staufenbiel and Paganetti, 2000) , with minor modifications, using the mAb 4G8. Briefly, formic acid extracts from AD human brains, control mice, and AD11 mice were homogenized as previously described . After separation on a 15% Tricine/Tris gel containing 8 M urea, proteins were transferred to PVDF membranes (Hybond-P, Amersham Pharmacia Biotech, Little Chalfont, CA) and Western blotting. After incubation overnight with mAb 4G8 and with anti-mouse biotinylated antibody, Western blots were developed using the ABC method developed with nitrobluetetrazolium and 5-bromo-4-chloro-3-indolyl phosphate toluidinium salt.
